Archive · 18 Sep 2025
Indian Pharma: Growth Expected Despite US Market Concerns
The Indian pharmaceutical industry is expected to grow, but there are some worries about the US market.
They are anticipating growth in the next year, with strong domestic demand.
They are launching new products, and doing well in Europe.
They are cautious about the US, due to possible tariffs and regulatory issues.
This might slow growth in the US.
The companies are also spending on research and development for new medicines.
Indian pharma industry projects 7-9% growth in FY26.
US market growth expected to slow to 3-5% due to multiple factors.
Domestic market expected to grow 8-10% in FY26.
Europe's market expected to increase 10-12%.
US regulatory scrutiny and tariffs pose ongoing risks.
- Who
- Indian Pharmaceutical Industry
- What
- Is projected to grow despite challenges
- When
- FY26
- Where
- Domestic, US, and European markets
- Why
- Fueled by domestic demand, new product launches, and growth in Europe.
Challenges to Growth
Market Stability
Market Uncertainty
Challenges to Growth
Concerns about US tariffs, pricing policies, and FDA scrutiny could slow revenue growth.
Market Stability
Strong domestic demand, new product launches, and geographic expansion support steady growth.
- Projected FY26 Growth
- 7-9%
- Domestic Market Growth (FY26)
- 8-10%
- US Market Growth (FY26)
- 3-5%
- Europe Market Growth (FY26)
- 10-12%
- R&D Spending
- 6-7% of revenues
Sources
Indian pharma firms plan ₹45,000 cr capex in FY26, says ICRA
Indian Pharma Sector To Log 7-9% Growth In FY26 Despite US Headwinds: ICRA
Indian pharma companies’ revenue to grow 7-9 pc in FY26 amidst US market risks: Report
API makers to hold strong despite strong imports from China - Economy News
